Compare Expedia Group Inc (EXPE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Twist Bioscience Corp — how do they compare? Expedia Group Inc trades at $269.5 (market cap $32.42B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Expedia Group Inc is far larger — about 3.2× Twist Bioscience Corp's market cap, and Expedia Group Inc pays a 0.71% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Twist Bioscience Corp for 27 Days on average.
| EXPE | TWST | |
|---|---|---|
Market Cap | $32.42B | $10.08B |
Volume | 1,940,671 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $205.00 |
52-Week Low | $188.51 | $25.45 |
Typical Hold Time | 48 Days | 27 Days |
Enterprise Value | $30.98B | $10.01B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $258.86, down 0.38% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company demonstrates strong revenue growth from $14.73B in 2025 to projected $15.7B in 2026, with net income margins improving to 12.97%. Recent earnings beats and a 47.37% analyst buy rating support the positive outlook, though competition from AI travel agents presents headwinds.
The stock offers significant upside to the $335.06 consensus price target, representing 29% potential appreciation. Strong cash flow generation and improving profitability metrics support the bullish case, but investors must monitor competitive threats from AI disruption and recent layoffs indicating operational challenges. The current valuation at 16.28 P/E appears reasonable given growth prospects.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
